XML 19 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue:        
Total revenue $ 155,973 $ 44,032 $ 218,766 $ 111,320
Operating costs and expenses:        
Cost of goods sold $ 3,266 $ 2,207 $ 9,746 $ 6,253
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 75,880 $ 58,476 $ 273,123 $ 174,792
Selling, general and administrative 25,853 (48,981) 89,186 64,157
Total operating costs and expenses 104,999 11,702 372,055 245,202
Income (loss) from operations 50,974 32,330 (153,289) (133,882)
Interest and other, net        
Interest expense (109) (580) (965) (1,864)
Interest income and other income (expenses), net (1,303) 1,482 (2,120) 5,292
Total interest and other, net (1,412) 902 (3,085) 3,428
Income (loss) before income taxes 49,562 33,232 (156,374) (130,454)
Provision for income taxes 106 215 235 190
Investment income (loss) in unconsolidated variable interest entity 342 (13) 664 (13)
Net income (loss) $ 49,798 $ 33,004 $ (155,945) $ (130,657)
Net income (loss) per share:        
Basic $ 0.54 $ 0.36 $ (1.69) $ (1.46)
Diluted $ 0.54 $ 0.35 $ (1.69) $ (1.46)
Weighted average number of common shares used to calculate net income (loss) per share:        
Basic 92,644 90,558 92,206 89,414
Diluted 92,808 93,678 92,206 89,414
License Revenue [Member]        
Revenue:        
Total revenue $ 116,434 $ 0 $ 116,434 $ 0
Development and Other Revenue [Member]        
Revenue:        
Total revenue 26,097 20,663 60,325 59,065
Product Revenue, Net [Member]        
Revenue:        
Total revenue 13,442 22,683 42,175 43,331
Drug Product Revenue [Member]        
Revenue:        
Total revenue $ 0 $ 686 $ (168) $ 8,924